close
Add to watchlist
ZIOPHARM Oncology Inc (ZIOP)
ZIOPHARM Oncology, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of proprietary small molecule drug candidates that are related to cancer therapeutics. Its primary product includes Palifosfamide (Zymafos or ZIO-201), which is in phase II randomized controlled trial for the treatment of metastatic or unresectable soft tissue sarcoma as front- or second-line therapy. The company's products in Phase I and/or II studies include Darinaparsin (Zinapar or ZIO-101), a novel anti-mitochondrial agent for the treatment of acute promyelocytic leukemia and for various other cancers; and Indibulin (Zybulin or ZIO-301), a novel small molecular-weight tubulin polymerization inhibitor. It has collaboration agreement with Harmon Hill, LLC to provide consulting and other services related to the company's development and commercialization of oncology therapeutics. The company was founded in 2003 and is based in New York, New York.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 5.06 |
| Volume | 394908 |
| Volume Avg | 619561 |
| 52 Week High | 7.85 |
| 52 Week Low | 3.55 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -0.97 |
| EPS change Q/Q | -160% |
| EPS change Q/Q Yr ago | -47.73% |
| EPS change Q/Q next Q est | -150% |
| EPS change Y/Y | -31.58% |
| REV change Q/Q | -100% |
| REV change Q/Q Yr ago | -100% |
| EPS next Q est | -0.26 |
| EPS next Y est | -1.14 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |